While SET and PKCB have already been targeted for the treatment of CLL in experimental studies (49) and clinical trials for other lymphoma entities (52), our in silico simulations suggest that the simultaneous targeting of SET and PKCB would lead to a fully quiescent behavior in the CDKN2A/B and TP53 KO condition but would have no effect on the AKT hyperactivation simulation (fig. The gene discussed is CDKN2A; the disease is B-cell chronic lymphocytic leukemia.